These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 9345394)

  • 61. Interferon beta treatment for multiple sclerosis.
    Herndon RM
    Lancet; 1999 Feb; 353(9151):494-5; author reply 497-8. PubMed ID: 9989739
    [No Abstract]   [Full Text] [Related]  

  • 62. Mesenchymal stem cells for multiple sclerosis: can we find the answer?
    Tyndall A;
    Mult Scler; 2010 Apr; 16(4):386. PubMed ID: 20385716
    [No Abstract]   [Full Text] [Related]  

  • 63. Intrathecally administered natural human fibroblast interferon reduces exacerbations of multiple sclerosis. Results of a multicenter, double-blind study.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Jozefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Arch Neurol; 1987 Jun; 44(6):589-95. PubMed ID: 3579676
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Interferons in the treatment of multiple sclerosis: errors and misrepresentations.
    Herndon RM
    Arch Neurol; 2000 Mar; 57(3):426-7. PubMed ID: 10714676
    [No Abstract]   [Full Text] [Related]  

  • 65. A robust mixed linear model analysis for longitudinal data.
    Gill PS
    Stat Med; 2000 Apr; 19(7):975-87. PubMed ID: 10750063
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Hyperbaric oxygen treatment for multiple sclerosis.
    Adamson L
    Nurs Times; 1985 Nov 20-26; 81(47):47-8. PubMed ID: 3906577
    [No Abstract]   [Full Text] [Related]  

  • 67. Exercise, drug treatment, and the optimal care of multiple sclerosis patients.
    Johnson KB
    Ann Neurol; 1996 Apr; 39(4):422-3. PubMed ID: 8619519
    [No Abstract]   [Full Text] [Related]  

  • 68. Multicentre double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis.
    Jacobs L; Salazar AM; Herndon R; Reese PA; Freeman A; Josefowicz R; Cuetter A; Husain F; Smith WA; Ekes R
    Lancet; 1986 Dec 20-27; 2(8521-22):1411-3. PubMed ID: 2878272
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Autologous hematopoietic stem cell transplantation for multiple sclerosis--if confused or hesitant, remember: 'treat with standard immune suppressive drugs and if no inflammation, no response'.
    Burt RK; Balabanov R; Voltarelli J; Barreira A; Burman J
    Mult Scler; 2012 Jun; 18(6):772-5. PubMed ID: 22619224
    [No Abstract]   [Full Text] [Related]  

  • 70. Treating multiple sclerosis with information.
    Heesen C
    Mult Scler; 2010 Nov; 16(11):1302. PubMed ID: 21041328
    [No Abstract]   [Full Text] [Related]  

  • 71. Gut response. Therapy with ingested immunomodulatory proteins.
    Brod SA
    Arch Neurol; 1997 Oct; 54(10):1300-2. PubMed ID: 9341578
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Blinded sample size reestimation in event-driven clinical trials: Methods and an application in multiple sclerosis.
    Friede T; Pohlmann H; Schmidli H
    Pharm Stat; 2019 May; 18(3):351-365. PubMed ID: 30652403
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Altered peptide ligands and MS treatment.
    Conlon P; Steinman L
    Science; 2002 Jun; 296(5574):1801-2; author reply 1801-2. PubMed ID: 12053936
    [No Abstract]   [Full Text] [Related]  

  • 74. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Can we change the natural course of inflammatory bowel disease?
    Le Berre C; Danese S; Peyrin-Biroulet L
    Therap Adv Gastroenterol; 2023; 16():17562848231163118. PubMed ID: 37153497
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Interferon β for Multiple Sclerosis.
    Jakimovski D; Kolb C; Ramanathan M; Zivadinov R; Weinstock-Guttman B
    Cold Spring Harb Perspect Med; 2018 Nov; 8(11):. PubMed ID: 29311124
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Cognition and fatigue in patients with relapsing multiple sclerosis treated by subcutaneous interferon β-1a: an observational study SKORE.
    Benešová Y; Tvaroh A
    Ther Adv Neurol Disord; 2017 Jan; 10(1):18-32. PubMed ID: 28450892
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Drug treatment of multiple sclerosis.
    Polman CH; Uitdehaag BM
    West J Med; 2000 Dec; 173(6):398-402. PubMed ID: 11112758
    [No Abstract]   [Full Text] [Related]  

  • 79. Drug treatment of multiple sclerosis.
    Polman CH; Uitdehaag BM
    BMJ; 2000 Aug 19-26; 321(7259):490-4. PubMed ID: 10948033
    [No Abstract]   [Full Text] [Related]  

  • 80. Magnetic resonance in monitoring the natural history of multiple sclerosis and the effects of treatment.
    Filippi M; Rovaris M; Comi G
    Ital J Neurol Sci; 1996 Dec; 17(6):385-91. PubMed ID: 8978444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.